Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.
Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.
Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.
Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.